Search Results

In this bonus episode, BioSpace Vice President of Marketing Chantal Dresner and Angela Gabriel, content manager, life sciences careers, discuss how the job market shaped up in Q3 and what Q4 might hold.

Highlights M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher’s proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply. Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform’s entry point, are planned for Q4 2026. Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine dissolvable tablet for telehealth in Q1 2027. Rare pediatric NDA with voucher potential. Orphan drug and rare pediatric disease designation applications are planned for October 2026, with a pre-IND meeting in Q1 2027 and an NDA submission targeted for Q4 2028. Approval could earn a priority review voucher; recent vouchers have sold for US$100–155 million. Pipeline expansion into underserved markets. PharmaTher is evaluating three underserved markets where small-batch production is an advantage: ultra-rare diseases with no FDA-approved treatment, psychedelic medicines for clinical trials and special access, and discontinued medicines that mass manufacturing no longer serves. National emergency network. Every CraftMake™ placement can become a node that prints medical countermeasures on demand. PharmaTher plans to pursue readiness contracts with U.S. and Canadian agencies. New website and brand. PharmaTher has launched its new corporate website at PharmaTher.com, and PERSONALIZ3D™ is now M3DICINES™ (M3DICINES.com).

The third quarter offered positive signals for job seekers and talent acquisition teams. Explore BioSpace’s Biopharma Job Market Report Q3 2026 to get a closer look at hiring trends, workforce reductions and the evolving employment landscape across the industry.

Big Pharma companies including Bristol Myers Squibb, Johnson & Johnson and Novartis are among those that made or planned layoffs in Q3. Those cuts could affect over 1,800 employees, with New Jersey the hardest-hit state.

Amgen is awaiting another Phase 3 readout for the investigational Sjögren’s disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an FDA application.

Potential near-term commercialization through two synergistic business units: (i) a telehealth platform connecting patients with independent licensed healthcare providers and (ii) a North American network of pharmacy-based pharmaceutical 3D-printing systems for compounding medications, together forming a personalized medicine ecosystem

While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out hope for an overall survival win—but analysts say that outcome is now “less likely.”

Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.

Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with certain mutations; and Caribou Biosciences may be on its way out.

With weight loss topping 20% at 80 weeks in the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, Eli Lilly plans to file for retatrutide’s approval in the first quarter of 2027. Previously a filing was expected later this year.